Plain-English translation of ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new drug called , which is designed to help treat advanced hepatocellular carcinoma (a type of liver cancer). The medication works by targeting cancer cells and encouraging them to mature into normal liver cells — a strategy that has shown promise in laboratory and animal studies. Researchers want to find the right dose and confirm that this treatment is safe and effective for patients.
Current treatments for advanced liver cancer don't work well enough for many patients, and survival rates remain poor. This medication represents a different approach: instead of simply killing cancer cells, it tries to make them behave like healthy liver cells, which is a strategy that has been very successful in treating certain blood cancers.
You likely qualify if…
You likely don't qualify if…
You would receive as an intravenous infusion (delivered directly into a vein). The trial is designed in two phases: first, researchers will gradually increase the dose in small groups of patients to find the safest dose, and then test that dose in more patients to see if it works. Throughout the trial, you would have regular visits for blood tests, imaging scans, and check-ups to monitor how you respond to the medication and watch for any side effects.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China